Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GOAL.MD vs Wisp

By GLP-1 ScorecardUpdated

GOAL.MD
Site position #158

Higher score

WispFactor scores not reassessed.
Site position #258

Lower score

Score comparison

GOAL.MD has the higher recorded score — 68.6/100 to 64.4/100.

GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Compounded injection plans with manual reorders, plus separately priced physician care for brand-name prescriptions.

Before you choose

Before comparing the headline prices, the GOAL.MD review and the Wisp review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Alloy vs GOAL.MD and You + Me (He & She MD) vs Wisp compare each of them with another graded program, and the list of alternatives to GOAL.MD ranks the programs closest to GOAL.MD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the MyDrHank review covers one graded close to these two, at 68.2/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueGOAL.MD +15
65
50
Dose & formulationGOAL.MD +10
86
76
Clinical oversightWisp +14
68
82
Labs & monitoringEven
53
53
FulfillmentGOAL.MD +11
77
66
Contract termsEven
55
55
GOAL.MD · top barWisp · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricGOAL.MDWisp
WeighScore68.6/10064.4/100
GradeCC
Site position#158#258
Semaglutide$179/mo (month-to-month, compounded)$225/mo (compounded oral)
Tirzepatide$249/mo (flat-dose monthly, compounded)Not disclosed
CoverageAdvertises all 50 states; clinical and pharmacy eligibility applyCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
GOAL.MD

Site position #158 · C

Strengths

  • Compounded reorders require permission before charging
  • Advertised injection price stays the same across prescribed doses
  • Nutrition support and expedited shipping included in compounded plans
  • Advertises brand-name oral Wegovy access; medication costs extra

What to consider

  • Compounded orders become non-refundable when payment is processed
  • Lowest monthly equivalents require a twelve-month upfront payment
  • Brand-access page gives conflicting automatic-billing statements
  • Confirm the assigned dispensing pharmacy and its credentials
  • GOAL identifies a physician with historical discipline; Missouri ended restrictions in 2019 and records no current discipline at the October 2026 check
Wisp

Site position #258 · C

Factor scores not reassessed.

Strengths

  • Lists a separate compounded drops offer
  • Describes monthly provider check-ins

What to consider

  • The consultation price does not establish the pharmacy bill
  • Confirm state eligibility and the cancellation cutoff for your plan

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard